{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:44:11Z","timestamp":1757313851726,"version":"3.38.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1053\/j.semnuclmed.2025.02.001","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T20:23:57Z","timestamp":1740687837000},"page":"252-263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Current and Future Perspective of PET\/CT in Response Assessment of Malignant Pleural Mesothelioma"],"prefix":"10.1053","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6382-2626","authenticated-orcid":false,"given":"Manar","family":"Badarna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6057-778X","authenticated-orcid":false,"given":"Zohar","family":"Keidar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8978-4021","authenticated-orcid":false,"given":"Elite","family":"Arnon-Sheleg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0001","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jtho.2023.01.095","article-title":"Global incidence, risk factors, and temporal trends of mesothelioma: a population-based study","volume":"18","author":"Huang","year":"2023","journal-title":"J Thoracic Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0002","doi-asserted-by":"crossref","first-page":"1204722","DOI":"10.3389\/fonc.2023.1204722","article-title":"Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies","volume":"13","author":"Sahu","year":"2023","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0003","doi-asserted-by":"crossref","first-page":"72","DOI":"10.6004\/jnccn.2024.0014","article-title":"Mesothelioma: pleural, version 1.2024 featured updates to the NCCN Guidelines","volume":"22","author":"Stevenson","year":"2024","journal-title":"JNCCN J Natl Comprehens Cancer Netw"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0004","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.thorsurg.2020.08.005","article-title":"The molecular basis of malignant pleural mesothelioma","volume":"30","author":"Wadowski","year":"2020","journal-title":"Thorac Surg Clin"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.02.001_bib0005","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province","volume":"17","author":"Wagner","year":"1960","journal-title":"Br J Ind Med"},{"year":"2014","series-title":"Chrysotile Asbestos","key":"10.1053\/j.semnuclmed.2025.02.001_bib0006"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0007","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.21037\/tlcr.2019.11.11","article-title":"Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted\/banned asbestos use","volume":"9","author":"Alpert","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0008","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.3892\/ol.2016.4174","article-title":"Simian virus 40 may be associated with developing malignant pleural mesothelioma","volume":"11","author":"Thanh","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0009","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1586\/ers.11.51","article-title":"Simian virus 40 transformation, malignant mesothelioma and brain tumors","volume":"5","author":"Qi","year":"2011","journal-title":"Expert Rev Respir Med"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0010","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jcp.22724","article-title":"Malignant mesothelioma: facts, myths, and hypotheses","volume":"227","author":"Carbone","year":"2012","journal-title":"J Cell Physiol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0011","doi-asserted-by":"crossref","first-page":"8456","DOI":"10.1158\/0008-5472.CAN-07-2232","article-title":"SV40 multiple tissue infection and asbestos exposure in a hyperendemic area for malignant mesothelioma","volume":"67","author":"Comar","year":"2007","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0012","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s10552-009-9357-4","article-title":"Ionizing radiation: a risk factor for mesothelioma","volume":"20","author":"Goodman","year":"2009","journal-title":"Cancer Caus Contr"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0013","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/cncr.22526","article-title":"Therapeutic radiation for lymphoma: risk of malignant mesothelioma","volume":"109","author":"Teta","year":"2007","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0014","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1200\/JCO.2013.49.9616","article-title":"Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma","volume":"31","author":"Chirieac","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0015","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Mesothelioma: Pleural. Version 1.2025. NCCN; November 21, 2024. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/meso_pleural.pdf. Accessed January 4, 2025."},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.02.001_bib0016","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.3390\/jcm10112470","article-title":"Molecular fingerprints of malignant pleural mesothelioma: not just a matter of genetic alterations","volume":"10","author":"Lorenzini","year":"2021","journal-title":"J Clin Med"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0017","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMra1912719","article-title":"Perspectives on the treatment of malignant pleural mesothelioma","volume":"385","author":"Janes","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0018","first-page":"491","article-title":"Malignant pleural mesothelioma: an epidemiological perspective","volume":"1","author":"Robinson","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"issue":"19","key":"10.1053\/j.semnuclmed.2025.02.001_bib0019","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.3390\/jcm13195837","article-title":"Malignant Pleural Mesothelioma: A Comprehensive Review","volume":"13","author":"Jain","year":"2024","journal-title":"J Clin Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.02.001_bib0020","first-page":"e20210129","article-title":"Malignant pleural mesothelioma: an update","volume":"47","author":"Hajj","year":"2021","journal-title":"J Bras Pneumol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0021","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.21037\/jtd-20-2761","article-title":"Epidemiology, diagnosis and treatment of the malignant pleural mesothelioma, a narrative review of literature","volume":"13","author":"Schumann","year":"2021","journal-title":"J Thorac Dis"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0022","first-page":"1","article-title":"Update on biology and management of mesothelioma","volume":"30","author":"Asciak","year":"2021","journal-title":"Europ Respirat Rev"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0023","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2559.1997.5460776.x","article-title":"Pathology of malignant mesothelioma","volume":"30","author":"Attanoos","year":"1997","journal-title":"Histopathology"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0024","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.3389\/fonc.2020.01742","article-title":"The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review","volume":"10","author":"Rozitis","year":"2020","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/ajco.12043","article-title":"Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: trends in Australia and a literature review","volume":"9","author":"Linton","year":"2013","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0026","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/COC.0000000000000225","article-title":"Trimodality treatment of malignant pleural mesothelioma an institutional review","volume":"41","author":"Kapeles","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0027","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.lungcan.2009.08.019","article-title":"Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with Cisplatin\/Pemetrexed and radiotherapy","volume":"71","author":"B\u00f6l\u00fckbas","year":"2011","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.02.001_bib0028","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jtho.2017.02.026","article-title":"Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma","volume":"12","author":"Shaikh","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0029","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/ejcts\/ezy385","article-title":"Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy","volume":"55","author":"Frick","year":"2019","journal-title":"Euro J Cardio-Thoracic Surge"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0030","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"The Lancet"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0031","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"The Lancet"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2017.08.003","article-title":"The role of radical radiotherapy in the management of malignant pleural mesothelioma: a systematic review","volume":"125","author":"Ashton","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0033","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jtho.2022.11.018","article-title":"Considerations for imaging of malignant pleural Mesothelioma: a consensus statement from the International Mesothelioma Interest Group","volume":"18","author":"Katz","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0034","first-page":"134","article-title":"Diagnostic imaging and workup of malignant pleural mesothelioma","volume":"88","author":"Cardinale","year":"2017","journal-title":"Acta Biomedica"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0035","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.rxeng.2023.03.005","article-title":"Analysis of invasive diagnostic techniques for pathological confirmation of pleural mesothelioma","volume":"66","author":"G\u00f3mez Herrero","year":"2024","journal-title":"Radiolog\u00eda (English Edition)"},{"issue":"1148","key":"10.1053\/j.semnuclmed.2025.02.001_bib0036","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20220339","article-title":"The lung cancers: staging and response, CT, 18F-FDG PET\/CT, MRI, DWI: review and new perspectives","volume":"96","author":"Owens","year":"2023","journal-title":"Br J Radiol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0037","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11604-023-01480-5","article-title":"An overview on multimodal imaging for the diagnostic workup of pleural mesothelioma","volume":"42","author":"Gabelloni","year":"2024","journal-title":"JPN J Radiol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0038","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s11604-016-0555-1","article-title":"Present and future roles of FDG-PET\/CT imaging in the management of malignant pleural mesothelioma","volume":"34","author":"Kitajima","year":"2016","journal-title":"JPN J Radiol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0039","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1053\/j.semnuclmed.2022.04.011","article-title":"FDG PET\/CT for primary staging of lung cancer and mesothelioma","volume":"52","author":"Kandathil","year":"2022","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0040","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1053\/j.semnuclmed.2022.07.005","article-title":"FDG PET\/CT for staging and restaging malignant mesothelioma","volume":"52","author":"Lopci","year":"2022","journal-title":"Semin Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.02.001_bib0041","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/jcm11010033","article-title":"The Prognostic Value of 18F-FDG PET Imaging at Staging in Patients with Malignant Pleural Mesothelioma: A Literature Review","volume":"11","author":"Taralli","year":"2021","journal-title":"J Clin Med"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0042","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1177\/02841851221085378","article-title":"Prognostic value of 18F-FDG PET\/CT in malignant pleural mesothelioma: a meta-analysis","volume":"64","author":"Wang","year":"2023","journal-title":"Acta Radiol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0043","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0044","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jtho.2018.04.034","article-title":"Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (Version 1.1)","volume":"13","author":"Armato","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0045","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0046","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1200\/JCO.2006.06.8999","article-title":"Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0047","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/annonc\/mds537","article-title":"Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma","volume":"24","author":"Tsutani","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0048","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejrad.2016.11.009","article-title":"Metabolic response assessment with 18F-FDG-PET\/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma","volume":"86","author":"Kanemura","year":"2017","journal-title":"Eur J Radiol"},{"issue":"63","key":"10.1053\/j.semnuclmed.2025.02.001_bib0049","doi-asserted-by":"crossref","first-page":"6816","DOI":"10.18632\/oncotarget.27324","article-title":"Clinical utility of FDG-PET\/CT for post-surgery surveillance of malignant pleural mesothelioma - Comparison with contrast-enhanced CT","volume":"10","author":"Kitajima","year":"2019","journal-title":"Oncotarget"},{"issue":"36","key":"10.1053\/j.semnuclmed.2025.02.001_bib0050","doi-asserted-by":"crossref","first-page":"58105","DOI":"10.18632\/oncotarget.11171","article-title":"Comparison of the EORTC criteria and PERCIST in solid tumors: a pooled analysis and review","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0051","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/MNM.0000000000001223","volume":"41","author":"Kitajima","year":"2020","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0052","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.lungcan.2009.04.015","article-title":"Combined FDG-PET\/CT in response evaluation of malignant pleural mesothelioma","volume":"67","author":"Veit-Haibach","year":"2010","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.02.001_bib0053","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jtho.2019.08.012","volume":"14","author":"Gill","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0054","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0055","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2967\/jnumed.118.213652","article-title":"18 F-FDG PET\/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma","volume":"60","author":"Ito","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0056","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13051098","article-title":"Response to immune checkpoint inhibitor therapy in patients with unresectable recurrent malignant pleural mesothelioma shown by FDG-pet and CT","volume":"13","author":"Kitajima","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0057","doi-asserted-by":"crossref","first-page":"408","DOI":"10.18632\/oncotarget.28594","article-title":"Comparison of FDG-PET\/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma","volume":"15","author":"Kitajima","year":"2024","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0058","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/ejcts\/ezv422","article-title":"Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma","volume":"49","author":"Kircheva","year":"2016","journal-title":"Europ J Cardio-Thorac Surg"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.02.001_bib0059","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0022-5223(98)70274-0","article-title":"Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma","volume":"115","author":"Pass","year":"1998","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0060","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2214\/AJR.11.7015","article-title":"Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume","volume":"198","author":"Gill","year":"2012","journal-title":"Am J Roentgenol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0061","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2017.05.23","article-title":"Volumetric assessment in malignant pleural mesothelioma","volume":"5","author":"Murphy","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0062","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00330-008-0918-9","article-title":"Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT","volume":"18","author":"Plathow","year":"2008","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0063","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1158\/1078-0432.CCR-09-2313","article-title":"A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters","volume":"16","author":"Nowak","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0064","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1245\/s10434-010-1107-z","article-title":"Volume-based parameter of 18F-FDG PET\/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications","volume":"17","author":"Lee","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0065","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2967\/jnumed.107.042333","article-title":"Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans","volume":"48","author":"Francis","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0066","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4103\/jcrt.JCRT_217_19","article-title":"The role of volumetric method in the assessment of chemotherapy response and predicting survival in malignant pleural mesothelioma","volume":"17","author":"Urfali","year":"2021","journal-title":"J Cancer Res Ther"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0067","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s00259-018-4056-6","article-title":"FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients","volume":"45","author":"Incerti","year":"2018","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0068","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1053\/j.semnuclmed.2025.02.001_bib0069","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group","volume":"35","author":"Young","year":"1999","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2025.02.001_bib0070","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors","volume":"50 Suppl 1","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.02.001_bib0071","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13550-019-0473-1","article-title":"Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST","volume":"9","author":"Goldfarb","year":"2019","journal-title":"EJNMMI Res"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.02.001_bib0072","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.116.188839","article-title":"Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET\/CT Imaging in Patients with Advanced Melanoma","volume":"58","author":"Cho","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0073","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s00259-017-3870-6","article-title":"Absolute number of new lesions on 18F-FDG PET\/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab","volume":"45","author":"Anwar","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0074","first-page":"127","article-title":"Clinical staging of malignant pleural mesothelioma: current perspectives","volume":"8","author":"Bonomi","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0075","article-title":"Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET\/CT scan in patients with malignant pleural mesothelioma","volume":"15","author":"Lim","year":"2020","journal-title":"PLoS One"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0076","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.ejcts.2008.07.050","article-title":"Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-d-glucose positron emission tomography\/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy","volume":"34","author":"S\u00f8rensen","year":"2008","journal-title":"Europ J Cardio-Thorac Surg"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0077","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.2214\/AJR.19.21227","article-title":"Lung cancer recurrence: 18F-FDG PET\/CT in clinical practice","volume":"213","author":"Kandathil","year":"2019","journal-title":"Am J Roentgenol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0078","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2009\/650864","article-title":"Pleural FDG uptake more than a decade after Talc Pleurodesis","volume":"2009","author":"Peek","year":"2009","journal-title":"Case Rep Med"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0079","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2214\/AJR.04.1912","article-title":"CT of pleural abnormalities in lymphangioleiomyomatosis and comparison of pleural findings after different types of pleurodesis","volume":"186","author":"Avila","year":"2006","journal-title":"Am J Roentgenol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0080","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/686153","article-title":"Persistent Inflammation in Pulmonary Granuloma 48 Years after Talcage Pleurodesis, Detected by FDG-PET\/CT","volume":"2012","author":"Fanggiday","year":"2012","journal-title":"Case Rep Med"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0081","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7150\/jca.2586","article-title":"FDG PET\/CT response evaluation in malignant pleural mesothelioma pa-tients treated with talc pleurodesis and chemotherapy","volume":"3","author":"Genestreti","year":"2012","journal-title":"J Cancer"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.02.001_bib0082","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/RLU.0b013e3181bece11","article-title":"F-18 FDG PET\/CT characterization of talc pleurodesis-induced pleural changes over time: a retrospective study","volume":"34","author":"Nguyen","year":"2009","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0083","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1200\/EDBK_200643","article-title":"Patterns of Response and Progression to Immunotherapy","volume":"38","author":"Borcoman","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0084","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jtho.2017.09.001","article-title":"Pseudoprogression associated with clinical deterioration and worsening quality of life in malignant pleural mesothelioma","volume":"13","author":"Barnet","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.02.001_bib0085","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11604-018-0786-4","article-title":"Hilar and mediastinal sarcoid-like reaction after the treatment of malignant tumors: imaging features and natural course on 18F-FDG-PET\/CT","volume":"37","author":"Kaneko","year":"2019","journal-title":"Jpn J Radiol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.02.001_bib0086","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.3390\/diagnostics11061009","article-title":"Sarcoid-Like Reaction in Non-Hodgkin's Lymphoma-A Diagnostic Challenge for Deauville Scoring on 18F-FDG PET\/CT Imaging","volume":"11","author":"Winkelmann","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.02.001_bib0087","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12032-021-01477-y","article-title":"Sarcoid-like reaction in cases treated by checkpoint inhibitors","volume":"38","author":"Paydas","year":"2021","journal-title":"Med Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.02.001_bib0088","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s13256-019-2137-1","article-title":"Sarcoid- like Phenomenon - ustekinumab induced granulomatous reaction mimicking diffuse metastatic disease: a case report and review of the literature","volume":"13","author":"Gad","year":"2019","journal-title":"J Med Case Rep"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0089","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1111\/1759-7714.14011","article-title":"Sarcoid-like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab","volume":"12","author":"Takamori","year":"2021","journal-title":"Thorac Cancer"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.02.001_bib0090","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40291-024-00756-4","article-title":"Emerging Radiopharmaceuticals in Pet Imaging for Mesothelioma: A Review of [18F]FDG Alternatives","volume":"29","author":"Guglielmo","year":"2025","journal-title":"Mol Diagn Ther"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0091","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lungcan.2015.07.015","article-title":"Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT","volume":"90","author":"Francis","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0092","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2967\/jnumed.121.262206","article-title":"68Ga-Pentixafor PET\/CT for detection of chemokine receptor CXCR4 expression in myeloproliferative neoplasms","volume":"63","author":"Kraus","year":"2022","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.02.001_bib0093","doi-asserted-by":"crossref","first-page":"9288","DOI":"10.18632\/oncotarget.7063","article-title":"[68Ga]Pentixafor-PET\/CT for imaging of chemokine receptor 4 expression in small cell lung cancer\u2013initial experience","volume":"7","author":"Lapa","year":"2016","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0094","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MNM.0000000000001702","article-title":"Comparison of the role of 18F-fluorodeoxyglucose PET\/computed tomography and 68Ga-labeled FAP inhibitor-04 PET\/CT in patients with malignant mesothelioma","volume":"44","author":"G\u00fczel","year":"2023","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0095","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.2967\/jnumed.124.267473","article-title":"Fibroblast activation protein-directed imaging outperforms 18F-FDG PET\/CT in malignant mesothelioma: a prospective, single-center, observational trial","volume":"65","author":"Kessler","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0096","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","article-title":"Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities","volume":"28","author":"Fendler","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.02.001_bib0097","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/cancers16040839","article-title":"FAPi-Based Agents in Thyroid Cancer: A New Step towards Diagnosis and Therapy? A Systematic Review of the Literature","volume":"16","author":"Guglielmo","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0098","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","article-title":"Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies","volume":"50","author":"Priv\u00e9","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.02.001_bib0099","first-page":"192","article-title":"Current Advances in CAR T Cell Therapy for Malignant Mesothelioma","volume":"2","author":"Klampatsa","year":"2020","journal-title":"J Cell Immunol"},{"key":"10.1053\/j.semnuclmed.2025.02.001_bib0100","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1245\/s10434-010-1107-z","article-title":"Volume-based parameter of 18F-FDG PET\/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications","volume":"17","author":"Lee","year":"2010","journal-title":"Ann Surg Oncol"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825000091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825000091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T23:41:01Z","timestamp":1741909261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299825000091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0001299825000091"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.02.001","relation":{},"ISSN":["0001-2998"],"issn-type":[{"type":"print","value":"0001-2998"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and Future Perspective of PET\/CT in Response Assessment of Malignant Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}